6th European Post-Chicago Melanoma/Skin Cancer Meeting

Transcription

6th European Post-Chicago Melanoma/Skin Cancer Meeting
Congress Presidents
Axel Hauschild, Kiel, Germany
Claus Garbe, Tuebingen, Germany
Final Program (updated: 23/03/16)
6 th European Post-Chicago
Melanoma/Skin Cancer Meeting
Results and Interpretations of ASCO Presentations 2016:
Interdisciplinary Global Conference on News
in Melanoma/Skin Cancer
June 30 th– July 1st, 2016
Munich, Germany
Leonardo Royal Hotel
www.melanomaglobal2016.org
Under the auspices of the
European Association
of Dermato-Oncology
CONTENT
WELCOME MESSAGE 01
PROGRAM AT A GLANCE 02
PROGRAM 04
Thursday, June 30th 04
Friday, July 1st 07
CONGRESS FACULTY 10
FLOOR PLAN 13
SATELLITE SYMPOSIA OVERVIEW 14
GENERAL INFORMATION 17
SPONSORS 20
REGISTRATION FORM 21
WELCOME MESSAGE
Dear colleagues and friends,
Since the first Post-Chicago Meeting on Melanoma/Skin Cancer took place in 2011, it has attracted up
to 580 participants each year from all over the world. The interactive congress offers a comprehensive
overview on all new developments in melanoma diagnostics and therapy and a direct communication
with the world´s leading experts in these fields.
Presently, there are many new developments in melanoma diagnostics and treatment. New devices may
enable a more precise diagnostics of primary melanoma and allow earlier detection. For metastatic
melanoma, there is a rapid change of therapeutic approaches. New drugs like BRAF- and MEK-inhibitors
and CTLA4 and PD1-antibodies are already established in melanoma treatment. However, it remains an
open question how to combine them and how they should be sequentially applied. Additionally, the
significance of other drugs and vaccines like T-VEC has still to be determined.
Nevertheless, it will be the main target for all of us to choose the right patients for the right drugs! The
aim of the Interdisciplinary Global Conference on Developing New Treatments for Melanoma/Skin Cancer in Munich is to grant a deep overall insight into the development of new drugs for melanoma and
other cutaneous malignancies. The lively interaction of clinicians, as well as experts in translational and
basic research, and representatives of the pharmaceutical industry, guarantees a successful outcome for
every participant.
International key opinion leaders on melanoma will be invited to give an overview throughout specified presentations, to present latest clinical trial results, and to discuss on exciting new drugs with the
audience. In addition to the scientific value of this meeting, every participant may seize the given opportunity to interact with experts in a familiar setting in one of the most interesting cities of Germany.
Please join us for this event and submit your own studies and case presentations as free communications
and as posters.
We look forward to welcoming you in Munich in June 2016!
Axel Hauschild, MD
Congress President
Claus Garbe, MD
Congress President
1
PROGRAM AT A GLANCE
THURSDAY, JUNE 30TH
ROYAL BALLROOM
R1+R2
8:00
9:00
Opening of the conference
SYMPOSIUM I
My personal highlights at ASCO 2016
10:00
11:00
KEY NOTE LECTURE
COFFEE BREAK
12:00
SATELLITE SYMPOSIUM I
with lunch (platinum sponsor)
13:00
SYMPOSIUM II
Adjuvant treatment of melanoma
PARALLEL SESSION I
Prognostic and predictive markers for tumor response
14:00
COFFEE BREAK
15:00
SATELLITE SYMPOSIUM II
(platinum sponsor)
16:00
SYMPOSIUM III
Current Clinical Trials I
17:00
18:00
SYMPOSIUM IV
Frequent and rare adverse events of new drugs
SYMPOSIUM
2
SATELLITE SYMPOSIUM
KEY NOTE LECTURE
PARALLEL SESSION
FREE COMMUNICATIONS
FRIDAY, JULY 1ST
ROYAL BALLROOM
8:00
R1+R2
POSTER VIEWING & POSTER AWARD
KEY NOTE LECTURE
9:00
SATELLITE SYMPOSIUM III
(platinum sponsor)
10:00
COFFEE BREAK
SATELLITE SYMPOSIUM IV
(platinum sponsor)
11:00
COFFEE BREAK
12:00
SATELLITE SYMPOSIUM V
with lunch (platinum sponsor)
13:00
SYMPOSIUM V
Current Clinical Trials II
14:00
15:00
PARALLEL SESSION II
EADO Forum: Our most interesting
melanoma cases
COFFEE BREAK
SATELLITE SYMPOSIUM VI
(platinum sponsor)
16:00
17:00
SYMPOSIUM VI
Standard of care for BRAF mutated melanoma?
Pros and Cons
FREE COMMUNICATIONS
18:00
CLOSING REMARKS
3
THURSDAY, JUNE 30TH
09:30 OPENING OF THE CONFERENCE
ROYAL BALLROOM
CHAIRPERSON: AXEL HAUSCHILD, KIEL, GERMANY
EADO presidential address
09:40 –11:00 SYMPOSIUM I
ROYAL BALLROOM
My personal highlights at ASCO 2016
CHAIRPERSONS: SANJIV AGARWALA, BETHLEHEM, USA
CAROLA BERKING, MUNICH, GERMANY
09:40–10:00
10:05–10:25
10:30–10:50
… in immunotherapy
Michael A. Postow, New York, USA
… in targeted therapies
Olivier Michielin, Lausanne, Switzerland
… in non melanoma skin cancer
Celeste Lebbé, Paris, France
11:00 –11:30 KEY NOTE LECTURE
ROYAL BALLROOM
CHAIRPERSON: ROLAND KAUFMANN, FRANKFURT, GERMANY
11:00-11:30 Mutational testing in melanoma
Grant McArthur, Melbourne, Australia
11:30 –12:00 COFFEE BREAK
12:00 –13:30 SATELLITE SYMPOSIUM I with lunch
ROYAL BALLROOM
(platinum sponsor) (see page 14)
4
THURSDAY, JUNE 30TH
13:30 –14:30 SYMPOSIUM II
Adjuvant treatment of melanoma
ROYAL BALLROOM
CHAIRPERSONS: HUBERT PEHAMBERGER, VIENNA, AUSTRIA
JOHN KIRKWOOD, PITTSBURGH, USA
13:30 –13:42 Interferons – still worthwhile?
John Kirkwood, Pittsburgh, USA
13:45 –13:57Checkpoint inhibitors
Paolo Ascierto, Naples, Italy
14:00 –14:12Targeted therapies
Thomas Eigentler, Tuebingen, Germany
14:15 –14:27Neoadjuvant treatment
Dirk Schadendorf, Essen, Germany
13:30–14:30PARALLEL SESSION I
R1+R2
Prognostic and predictive markers for tumor response
CHAIRPERSONS:STEPHAN GRABBE, MAINZ, GERMANY
MICHELE MAIO, SIENA, ITALY
13:30–13:46
13:50–14:06
14:10–14:26
Prognostic markers in melanoma
Michele Maio, Sienna, Italy
Predictive markers for checkpoint inhibition
Benjamin Weide, Tuebingen, Germany
Predictive markers for targeted therapies
Jennifer Landsberg, Bonn, Germany
14:30 –15:00 COFFEE BREAK
15:00 –16:30 SATELLITE SYMPOSIUM II
ROYAL BALLROOM
(platinum sponsor) (see page 14)
5
THURSDAY, JUNE 30TH
16:30 –17:50 SYMPOSIUM III
Current Clinical Trials I
ROYAL BALLROOM
CHAIRPERSONS: KATHARINA KÄHLER, KIEL, GERMANY
PETER MOHR, BUXTEHUDE, GERMANY
16:30–16:45
16:50–17:05
17:10–17:25
17:30–17:45
Ocular Melanoma
Bastian Schilling, Essen, Germany
Mucosal Melanoma
Carola Berking, Munich, Germany
Brain Metastases
Friedegund Meier, Dresden, Germany
Soft Tissue/Skin Metastases
Sanjiv Agarwala, Bethlehem, USA
18:00 –19:00 SYMPOSIUM IV
ROYAL BALLROOM
Frequent and rare adverse events of new drugs
CHAIRPERSONS: CAROLINE ROBERT, PARIS, FRANCE
RALF GUTZMER, HANNOVER, GERMANY
18:00–18:10
18:15–18:25
18:30–18:40
18:45–18:55
6
Immune checkpoint inhibitors: Frequent AEs
Caroline Robert, Paris, France
Immune checkpoint inhibitors: Rare AEs
Lucie Heinzerling, Erlangen, Germany
Targeted therapies: Frequent AEs
Elisabeth Livingstone, Essen, Germany
Targeted therapies: Rare AEs
Celeste Lebbé, Paris, France
FRIDAY, JULY 1ST
08:00 –08:30 POSTER VIEWING & POSTER AWARD
ROYAL BALLROOM
POSTER GUIDES:RALF GUTZMER, HANNOVER, GERMANY
SELMA UGUREL, ESSEN, GERMANY
08:30 –09:30KEY NOTE LECTURE
ROYAL BALLROOM
CHAIRPERSONS: C
LAUS GARBE, TUEBINGEN, GERMANY
JOHN KIRKWOOD, PITTSBURGH, USA
08:30– 09:00
09:00– 09:30
How does immune checkpoint inhibition work?
Antoni Ribas, Los Angeles, USA
Is cure of metastatic melanoma on the horizon?
Caroline Robert, Paris, France
09:30–10:00 SATELLITE SYMPOSIUM III
ROYAL BALLROOM
(platinum sponsor) (see page 14)
10:00 –10:30 COFFEE BREAK
10:30 –11:30 SATELLITE SYMPOSIUM IV
ROYAL BALLROOM
(platinum
sponsor) (see page 14)
11:30 –12:00 COFFEE BREAK
7
FRIDAY, JULY 1ST
12:00 –13:30 SATELLITE SYMPOSIUM V with lunch
ROYAL BALLROOM
(platinum
sponsor) (see page 14)
13:30 –14:50 SYMPOSIUM V
Current Clinical Trials II
ROYAL BALLROOM
CHAIRPERSONS: CHRISTIAN BLANK, AMSTERDAM, NETHERLANDS
CHRISTOPH HÖLLER, VIENNA, AUSTRIA
13:30-13:42
13:46–13:58
14:02–14:14
14:18–14:30
14:34–14:46
MAGE-A3 vaccination (DERMA-trial): Final results
Brigitte Dréno, Nantes, France
BRAF + MEK inhibition
James Larkin, London, United Kingdom
NEMO trial: Binimetinib for NRAS-mutated melanoma
Reinhard Dummer, Zurich, Switzerland
Combined immune checkpoint inhibition
Christian Blank, Amsterdam, Netherlands
Chemosaturation in liver metastasis
Roland Kaufmann, Frankfurt, Germany
13:30–15:00 PARALLEL SESSION II
EADO Forum: Our most interesting melanoma cases
R1+R2
CHAIRPERSONS:KETTY PERIS, ROME, ITALY
IRIS ZALAUDEK, GRAZ, AUSTRIA
13:30–13:37
13:40–13:47
13:50–13:57
14:00–14:07
14:10–14:17
14:20–14:27
14:30–14:37
14:40–14:47
8
Case 1
Josef Malvehy, Barcelona, Spain
Case 2
Matilda Bylaitė Bučinskienė, Vilnius, Lithuania
Case 3
Ana Maria Forsea, Bucharest, Romania
Case 4
Ketty Peris, Rome, Italy
Case 5
Lidija Kandolf-Sekulovic, Belgrade, Serbia
Case 6
Judith Oláh, Szeged, Hungary
Case 7
Iris Zalaudek, Graz, Austria
Case 8
Petr Arenberger, Prague, Czech Republic
FRIDAY, JULY 1ST
15:00 –15:30 COFFEE BREAK
15:30 –17:00 SATELLITE SYMPOSIUM VI
ROYAL BALLROOM
(platinum sponsor) (see page 14)
17:00 –18:25 SYMPOSIUM VI
Standard of care for BRAF mutated melanoma? Pros and Cons
ROYAL BALLROOM
CHAIRPERSONS: SELMA UGUREL, ESSEN, GERMANY
AXEL HAUSCHILD, KIEL, GERMANY
17:00 –17:25
17:30 –17:55
18:00 –18:25
My first choice: Immunotherapy
Antoni Ribas, Los Angeles, USA
My first choice: BRAF + MEK inhibition
Dirk Schadendorf, Essen, Germany
Round Table Discussion
Australian View: Grant McArthur
European View: Reinhard Dummer / Dirk Schadendorf
US View: Sanjiv Agarwala / Antoni Ribas
17:00 –18:20 FREE COMMUNICATIONS
R1+R2
CHAIRPERSONS: JESSICA HASSEL, HEIDELBERG, GERMANY
JENNIFER LANDSBERG, BONN, GERMANY
18:25 –18:30 CLOSING REMARKS
ROYAL BALLROOM
Claus Garbe, Tuebingen, Germany
9
CONGRESS FACULTY
A
Sanjiv S. Agarwala , MD
Professor of Medicine
St. Lukes Cancer Center, Temple University
2145 Augusta DR
Center Valley PA 18034
USA
Phone: +1-610-297-0169
Email: [email protected]
Robert Andtbacka, MD
Associate Professor of Surgical Oncology
Department of Surgery
University of Utah
Huntsman Cancer Institute
2000 Circle of Hope Drive
Salt Lake City, Utah 84112-5550
USA
Phone: +1 801 587 8808
Email: [email protected]utah.edu
Petr Arenberger, MD
Department of Dermatology, Charles
University, 3rd School of Medicine
Srobarova 50
CZ-100 34 Prague
Czech Republic
Phone: +420-26716-3000
Email: [email protected]
Paolo A. Ascierto, MD
Melanoma, Cancer Immunotherapy
and Innovative Therapy Unit
Istituto Nazionale Tumori Fondazione
“G. Pascale”
Via Mariano Semmola
80131 Naples
Italy
Phone: +39-081-5903236
Email: [email protected]
B
Carola Berking, MD
Professor of Dermatology
Department of Dermatology and Allergology
University Hospital Munich (LMU)
Frauenlobstr. 9–11
80337 Munich
Germany
Phone: +49-89-4400-56225
Email: [email protected]
Christian Blank, MD
The Netherlands Cancer Institute
Plesmanlaan 121
1066 CX Amsterdam
The Netherlands
Phone: +31-20-512-2570
Email: [email protected]
10
Matilda Bylaite-Bucinskiene, MD
Professor of Dermatology
Chairwoman of the Centre of
Dermatovenereology
President of Lithuanian Association
of Dermatovenereologists
Vilnius University Hospital Santariskiu
Klinikos
Kairiukscio str. 2
08411 Vilnius
Lituania
Phone: +370-5-2720385
Email: [email protected]
D
Brigitte Dréno, MD
Professor of Dermatology
Chairman of the department
of Dermatology,
Director of the Unit of gene
and Cell Therapy,
Vice Dean for Research at the Faculty
of Medicine Nantes France
CHU Nantes
Place Alexis Ricordeau
44093 Cedex 01
France
Phone: +33-2-40083118
Email: [email protected]
Reinhard Dummer, MD
Professor of Dermatology
Department of Dermatology
Vice Chairman, University of Zurich
Hospital
Gloriastrasse 31
8091 Zurich
Switzerland
Phone: +41-442552507
Email: [email protected]
E
Thomas Eigentler, MD
Department of Dermatology
Eberhard Karls University
Liebermeister Str. 25
72076 Tuebingen
Germany
Phone: +49-7071-2985748
Email: [email protected]
med.uni-tuebingen.de
F
Ana Maria Forsea, MD
Assistant Professor for Dermatology
Department of Dermatology
Carol Davila University of Medicine and
Pharmacy Bucharest
Bulevardul Eroii Sanitari 8
Bucharest 050474
Romania
Phone: +40-21-3180462
Email: [email protected]
G
Claus Garbe, MD
Professor of Dermatology
Department of Dermatology
Eberhard Karls University
Liebermeister Str. 25
72076 Tuebingen
Germany
Phone: +49-7071-2987110
Email: [email protected]
Stephan Grabbe, MD
Professor of Dermatology, Director
Department of Dermatology
Johannes Gutenberg University
Langenbeckstr. 1
55131 Mainz
Germany
Phone: +49-6131-172910
Email: [email protected]
Ralf Gutzmer, MD
Professor of Dermatology
Skin Cancer Center, Department
of Dermatology
Hannover Medical School
Carl-Neuberg-Str. 1
30625 Hannover
Germany
Phone: +49-511-532-0
Email: [email protected]
H
Jessica Hassel, MD
Department of Dermatology, University
Hospital Heidelberg
and Nationales Centrum für Tumor­
erkrankungen (NCT)
Im Neuenheimer Feld 460
69120 Heidelberg
Germany
Phone: +49-6221-5638503
Email: [email protected]
Axel Hauschild, MD
Professor of Dermatology
Department of Dermatology
University of Kiel
Schittenhelmstr. 7
24105 Kiel
Germany
Phone: +49-431-5971852
Email: [email protected]
Lucie Heinzerling, MD, PhD, MPH
Professor
Department of Dermatology
University Hospital of Erlangen
Ulmenweg 18
91054 Erlangen
Germany
Phone: +49-9131-8539037
Email: [email protected]
Christoph Höller, MD
Professor of Dermatology
Department of Dermatology
Medical University of Vienna
Waehringer Gürtel 18-20
1090 Vienna
Austria
Phone: +43-1-404004786
Email: [email protected]
K
Katharina Kähler, MD
Department of Dermatology
University of Kiel
Schittenhelmstr. 7
24105 Kiel
Germany
Phone: +49-431-5971512
Email: [email protected]
Lidija Kandolf-Sekulovic, MD
Department of Dermatology
Military Medical Academy
Crnotravska 17
11000 Belgrade
Serbia
Phone: +381-113608583
Email: [email protected]
Roland Kaufmann, MD
Professor of Dermatology, Director
Department of Dermatology
Clinical Center J. W. Goethe University
Theodor-Stern-Kai 7
60590 Frankfurt am Main
Germany
Phone: +49-69-63015311
Email: [email protected]
John Kirkwood, MD
Usher Professor of Medicine, Dermatology
and Translational Science
Director Melanoma and Skin Cancer
Program
University of Pittsburgh Hillman Cancer
Center
Laboratory Suite L1.32c
5117 Centre Avenue, Suite 1.32
Pittsburgh PA 15213
USA
Phone: 001-412-623-7707
Email: [email protected]
L
Jennifer Landsberg, MD
Department of Dermatology
University of Bonn
Sigmund-Freud-Straße 25
53127 Bonn
Germany
Phone: +49-228-73-7021
Email: [email protected]
Josep Malvehy, MD
Director of the Melanoma Unit
Department of Dermatology
Hospital Clinic of Barcelona
C/Villarroel 170
08036 Barcelona
Spain
Phone: +34-933638920
Email: [email protected]
Grant McArthur, MD
Professor of Medicine
Head Cancer Therapeutics Program
Head Skin and Melanoma Service
Divisions of Cancer Medicine and Research
Peter MacCallum Cancer Centre
Locked Bag 1A’Beckett St
Melbourne 8006
Australia
Phone: +61-3-9656-3649
Email: [email protected]
James Larkin, MD
Consultant Medical Oncologist
The Royal Marsden Hospital
Fulham Road
London, SW3 6JJ
United Kingdom
Phone: +44-207-8118576
Email: [email protected]
Friedegund Meier, MD
Professor of Dermatooncology
Department of Dermatology
University Hospital Carl Gustav Carus
Technical University Dresden
Fetscherstr. 74
01307 Dresden
Germany
Phone: +49-351-4583677
Email: [email protected]
Celeste Lebbé, MD
Professor of Dermatology
Department of Dermatology
Hôpital Saint-Louis
1, Avenue Claude-Vellefaux
75010 Paris
France
Phone: +33-142494679
Email: [email protected]
Olivier Michielin, MD
Professor
Swiss Institute of Bioinformatics
Molecular Modeling Group
Quartier Sorge - Batiment Genopode
CH-1015 Lausanne
Switzerland
Phone: +41-21-692-4053
Email: [email protected]
Elisabeth Livingstone, MD
University Hospital Essen
Hauttumorzentrum
Hufelandstr. 55
45122 Essen
Germany
Phone: +49-201-7232431
Email: [email protected]
Peter Mohr, MD
Center of Dermatology
Elbe Klinikum Buxtehude
Am Krankenhaus 1
21614 Buxtehude
Germany
Phone: +49-41617036209/-6250
Email: [email protected]
M
O
Michele Maio, MD
Professor of Oncology
Department of Medical Oncology
and Immunotherapy
University Hospital of Siena
Strada della Scotte no. 14
53100 Siena
Italy
Phone: +39-0577586336
Email: [email protected]
Judit Oláh, MD
Department of Dermatology
University of Szeged
Koranyi Fasor 6
3720 Szeged
Hungary
Phone: +36-62-545984
Email: [email protected]
11
P
S
Hubert Pehamberger, MD
Professor and Chairman
Department of Dermatology
Medical University of Vienna
Waehringer Guertel 18-20
1090 Vienna
Austria
Phone: +43-1-404007710
Email: [email protected]
meduniwien.ac.at
Dirk Schadendorf, MD
Professor of Dermatology
Department of Dermatology
University Hospital Essen
Hufelanstr. 55
45147 Essen
Germany
Phone: +49-201-7232430
Email: [email protected]
Ketty Peris, MD
Department of Dermatology
Catholic University of Rome
Largo a Gemelli, 8
00168 Rome
Italy
Phone: +39-630154227
Email: [email protected]
Michael A. Postow, MD
Memorial Sloan Kettering Cancer Center
1275 York Avenue
New York, NY 10065
USA
Phone: +1-646-888-4589
Email: [email protected]
Paola Queirolo, MD
Presidente IMI
UOC Oncologia Medica
IRCCS San Martino-IST
Genova
Italy
Email: [email protected]
R
Antoni Ribas, MD
Professor of Medicine, Surgery and Molecular and Medical Pharmacology
University of California Los Angeles
UCLA Medical Center Hematology/
Oncology
100 UCLA Medical Plaza, Suite 550
Los Angeles, 90095
USA
Phone: +1-310-794-4955
Email: [email protected]
Caroline Robert MD, PhD
Head Dermatology
Gustave Roussy Institute
114 rue Edouard Vaillant
94801 Villejuif
France
Phone: +33-1-4211-64-97
Email: [email protected]
12
Bastian Schilling, MD
Department of Dermatology
University Hospital Essen
Hufelandstraße 55
45147 Essen
Germany
Phone: +49-201-723-83590
Email: [email protected]
U
Selma Ugurel, MD
Professor of Dermatology
Department of Dermatology
University Hospital Essen
Hufelandstr. 55
45122 Essen
Germany
Phone: +49-201-7234714
Email: [email protected]
W
Benjamin Weide, MD
Department of Dermatology
Eberhard Karls University
Liebermeister Str. 25
72076 Tuebingen
Germany
Phone: +49-7071-2984555
Email: [email protected]
med.uni-tuebingen.de
Z
Iris Zalaudek, MD
Division of Dermatology and Venerology
Non-Melanoma Skin Cancer Unit
Medical University of Graz
Auenbruggerplatz 8
8036 Graz
Austria
Phone: +43-6763328269
Email: [email protected]
ERDGESCHOSS/GROUND FLOOR
Terrasse/terrace
R7
R6
R5
SpeakerPreviewRoom
R3
künstlicher Wasserlauf/
artificial water point
R4
Service
R2
R1
Business
Center
Davidoff
Lounge
Lobby
Lifts
Registration
Desk
WC/
toilet
Moosacher Straße 90
Reception
Desk
Einfahrt Tiefgarage/
access underground parking
Foyer
Service
Terrasse/terrace
Back
Office
Hoteleingang/
hotel entrance
UNTERGESCHOSS/BASEMENT
LEONARDO
ROYAL HOTEL
MUNICH
FLOOR PLAN
13
SATELLITE SYMPOSIA OVERVIEW
THURSDAY, JUNE 30TH
2:00 –13:30 SATELLITE SYMPOSIUM I with lunch
1
Amgen (platinum sponsor) ROYAL BALLROOM
Unlocking antigens to ignite tumor immunity in melanoma
CHAIRPERSON: AXEL HAUSCHILD, KIEL, GERMANY
12:00–12:10Where we are now with melanoma treatment
Axel Hauschild, Kiel, Germany
12:10–12:45Oncolytic immunotherapy: from concept to clinical trials
Josep Malvehy, Barcelona, Spain
Robert Andtbacka, Salt Lake City, USA
12:45–13:20Practical considerations when using talimogene laherparepvec
Josep Malvehy, Barcelona, Spain
Robert Andtbacka, Salt Lake City, USA
13:20–13:30Future perspectives for melanoma and beyond
Axel Hauschild, Kiel, Germany
5:00 –16:30 SATELLITE SYMPOSIUM II
1
Bristol-Myers Squibb (platinum sponsor) ROYAL BALLROOM
The I-O approach in advanced melanoma – from mono- to
combination-therapy
CHAIRPERSON: CLAUS GARBE, TUEBINGEN, GERMANY
15:00–15:30Checkpoint modifiers in advanced melanoma – from mono- to
combination-therapy
James Larkin, London, United Kingdom
15:30–16:00Therapy of patients with advanced melanoma – an individual approach
Peter Mohr, Buxtehude, Germany
16:00–16:30Panel discussion & Final discussion
Claus Garbe, Tuebingen, Germany
James Larkin, London, United Kingdom
Peter Mohr, Buxtehude, Germany
and the audience
14
FRIDAY, JULY 1ST
9:30 –11:30 SATELLITE SYMPOSIUM III and IV
0
Roche (platinum sponsor) ROYAL BALLROOM
Your opinion matters – An interactive panel discussion on:
Hot topics of targeted therapies in BCC and melanoma
CHAIRPERSON: AXEL HAUSCHILD, KIEL, GERMANY
09:30–10:00 A
re there new therapeutic approaches for hedgehoc inhibitors in BCC?
Ralf Gutzmer, Hannover, Germany
10:00–10:30 Coffee Break
10:30–11:30The future of targeted therapies in melanoma?
Olivier Michielin, Lausanne, Switzerland
Reinhard Dummer, Zurich, Switzerland
Carola Berking, Munich, Germany
Grant McArthur, Melbourne, Australia
Christian Blank, Amsterdam, The Netherlands
2:00 –13:30 SATELLITE SYMPOSIUM V with lunch
1
Merck/MSD (platinum sponsor) ROYAL BALLROOM
Integrating immuno-oncology therapies into clinical practice:
An expert discussion
CHAIRPERSON: AXEL HAUSCHILD, KIEL, GERMANY
12:00–12:05 W
elcome and Introduction
Axel Hauschild, Kiel, Germany
12:05–12:45 Initiating treatment with checkpoint inhibitor monotherapy or combinations
Antoni Ribas, Los Angeles, USA
12:45–13:20Starting treatment with kinase inhibitors or immunotherapy
Grant McArthur, Melbourne, Australia
13:20–13:30Q & A session panel and concluding remarks program chair
15:30 –17:00 SATELLITE SYMPOSIUM VI
Novartis (platinum sponsor) ROYAL BALLROOM
A new era: Achieving personalized medicine in BRAF V600-mutant
metastatic melanoma
CHAIRPERSON: DIRK SCHADENDORF, ESSEN, GERMANY
15:30–15:40Welcome
Dirk Schadendorf, Essen, Germany
15:40–16:00BRAF V600 mutated metastatic melanoma:
Our current understanding of the disease
Christoph Höller, Vienna, Austria
16:00–16:20Practicing individualized treatment in the clinic
Paola Queirolo, Genova, Italy
16:20–16:40Onwards and upwards: A look to the future
Caroline Robert, Paris, France
16:40-16:55Q & A with the faculty
All
16:55-17:00Wrap up and close
Dirk Schadendorf, Essen, Germany
15
For patients with advanced melanoma
START WITH KEYTRUDA1
The first anti–PD-1 to demonstrate superior overall survival vs ipilimumab1
68% 1-year estimated overall survival rate vs 58% with ipilimumaba,b
Kaplan-Meier curve for overall survival
by treatment arm.
HR (95% CI)
vs ipilimumab
KEYTRUDA 10 mg/kg* Q3W 0.69 (0.52–0.90)
KEYTRUDA 10 mg/kg* Q2W 0.63 (0.47–0.83)
Ipilimumab
Risk reduction
vs ipilimumab
31%
37%
P value
0.00358
0.00052
KEYNOTE-006 study design: An open-label, multicenter, randomized, controlled Phase 3 trial that included patients with unresectable or metastatic
melanoma who were naïve to ipilimumab and who had received no more than 1 prior systemic therapy. Patients with BRAF V600E mutant melanoma
were not required to have received prior BRAF inhibitor therapy. Patients were randomized (1:1:1) to receive KEYTRUDA at a dose of 10 mg/kg* every
2 (n=279) or 3 weeks (n=277) or ipilimumab (n=278). The primary efficacy outcome measures were overall survival (OS) and progression-free survival
(PFS; as assessed by Integrated Radiology and Oncology Assessment [IRO] review using Response Evaluation Criteria In Solid Tumors [RECIST 1.1]).1
In intent-to-treat population. b Median not reached.
PD-1=programmed death receptor-1; Q3W=every 3 weeks; Q2W=every 2 weeks; HR=hazard ratio; CI=confidence interval.
* The recommended dosage according to Prescribing Information is 2 mg/kg every 3 weeks.
a
KEYTRUDA is indicated as monotherapy for the treatment of adult patients with unresectable or
metastatic melanoma.
KEYTRUDA®
KEYTRUDA® 50 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
Wirkstoff: Pembrolizumab Zus.: 1 Durchstechfl. enth.: Arzneil. wirks. Bestandt.: 50 mg Pembrolizumab. Nach Rekonstitution enth. 1 ml Lsg. 25 mg Pembrolizumab. Sonst. Bestandt.: L-Histidin, L-Histidinhydrochlorid-Monohydrat,
Sucrose, Polysorbat 80. Anw.: Als Monother. zur Behandl. d. fortgeschrittenen (nicht resezierbaren od. metastasierenden) Melanoms bei Erw. Gegenanz.: Überempf.-keit geg. d. Wirkstoff od. e. d. sonst. Bestandt. Stillzeit. Vorsicht
bei: Schwerer Einschränk. d. Nierenfunkt.; moderater od. schwerer Einschränk. d. Leberfunkt (nur begrenzte Daten).
Melanom d. Auges (limitierte Daten zu Sicherh. u. Wirksamk.). Kdr. u. Jugendl. < 18 J. (keine Daten). Behandl. nach
Risikoabwägung (keine Daten) bei Pat. mit: HIV-, Hepatitis-B- od. Hepatitis-C-Infekt.; akt., system. Autoimmunerkrank.;
Pneumonitis od. schwerer Überempf.-keit geg. e. and. monoklonalen Antikörper in d. Anamnese; laufender Ther. mit
Immunsuppressiva; schweren immunvermittelten NW unter Ipilimumab in d. Anamnese (jegliche Grad 4 od. Grad 3
Toxizität), d. eine Kortikosteroid-Behandl. über mehr als 12 Wo. erforderte (mehr als 10 mg/Tag Prednison od. Äquivalent in entspr. Dosierung); aktiv. Infekt.-erkrank. Schwangersch. Nebenw.: Sehr häufig: Diarrhö; Übelk. Hautausschl. (einschl. erythemat., follikul., general., makulärer, makulo-papulöser, papulöser, juck., vesikul. Hautausschl.);
Pruritus (einschl. Urtikaria, general. Pruritus). Arthralgie. Müdigk./Erschöpf. Häufig: Anämie; Thrombozytopenie. Hypophysitis (einschl. Hypophysenunterfunkt.); Hyperthyreose; Hypothyreose. Vermind. Appetit; Dehydrierung. Kopfschm.; Dysgeusie; periph. Neuropathie; Schwindel; Parästhesie. Trock. Augen. Vertigo. Hitzewall. Pneumonitis (einschl. interstit. Lungenerkrank.); Dyspnoe; Husten. Kolitis (einschl. mikroskop. Kolitis, Enterokolitis); Erbr.;
Abdominalschm. (einschl. abdominaler Beschw., Oberbauch- u. Unterbauchschm.); Obstipat.; Mundtrockenh.; aufgeblähtes Abdomen. Schwere Hautreakt. (einschl. exfoliativ. Dermatitis, Erythema multiforme, exfoliativ. Hautausschl., SJS, Grad ≥ 3 Pruritus, Hautausschl., general. Hautausschl., makulo-papulöser Hautausschl.); Vitiligo (einschl.
Hautdepigment.); Hauttrockenh.; Erythem; Ekzem; Hyperhidrose (einschl. Nachtschweiß); Hypopigment. d. Haut;
Alopezie. Myalgie; Muskelschw.; muskuloskelett. Schm. (einschl. muskuloskelett. Beschw.); Schm. in d. Extremitäten;
Rückenschm.; Arthritis; Muskelkrämpfe; muskuloskelett. Steifheit. Asthenie; Fieber; Schleimhautentzünd.; periph.
Ödeme; grippeähnl. Erkrank.; Schüttelfrost. Erhöh. Werte von: AST; ALT; alkal. Phosphatase im Blut; Gewichtsabnahme. Infus.-bedingte Reakt. (einschl. Überempf.-keit geg. d. AM, anaphylakt. Reakt., Überempf.-keit, „Cytokine-Release-Syndrom“). Gelegentl.: Divertikulitis; Pneumonie; Konjunktivitis; Herpes zoster; Candida-Infekt.; Influenza;
Harnwegsinfekt.; Herpes (simplex) im Mundbereich; Nasopharyngitis; Follikulitis. Tumorschm. Neutropenie; Lymphopenie; Leukopenie; Eosinophilie. Nebenniereninsuff.; Thyreoiditis (einschl. autoimmuner Thyreoiditis). Typ-I-Diabetes
mellitus; Hyponatriämie; Hypokaliämie; Hyperglykämie; Hypophosphatämie; Hypalbuminämie; Hypertriglyzeridämie;
Hypokalzämie; Hypomagnesiämie; Hypercholesterinämie; Hyperkalzämie; Hyperurikämie. Verwirrtheitszustand (einschl. Desorientier.); Schlaflosigk.; Ängstlichk.; vermind. Libido; Depress. Hypoästhesie; Lethargie; Neuralgie; periphere
sensor. Neuropathie; Hypogeusie; Restless-Legs-Syndrom; Hypotonie; Gedächtnisstör.; Tremor; Gleichgewichtsstör.;
Aufmerksamkeitsstör.; Hyperästhesie; Hypersomnie. Uveitis (einschl. Iritis u. Iridocyclitis); Augenschm.; Sehstör.;
Juckreiz d. Augen; Verschwommensehen; erhöh. Tränensekret.; okul. Hyperämie; Augenreiz.; Verfärb. d. Wimpern;
Photophobie; Mouches volantes. Perikarderguss; Palpitat. Hypotonie; Hitzegefühl/Flush; Raynaud-Syndrom. Pleuraschm.; Dysphonie; Giemen; verstopfte Nase; Schm. im Mundrachenraum; Hämoptoe; produkt. Husten; schmerzhafte
Atmung; Epistaxis; Nasenlaufen; Niesen. Pankreatitis; Dysphagie; Schm. im Mund; gastroösophag. Refluxkrank.;
Dyspepsie; Gastritis; Hämorrhoiden; Zahnerkrank.; Flatulenz.; Zahnfleischschm.; Stomatitis; Cheilitis. Hepatitis (einschl. autoimmune Hepatitis); Cholestase. Palmoplant. Erythrodysästhesie-Syndrom; Psoriasis; akneiforme Dermatitis;
Dermatitis; Farbveränd. d. Haare; Papeln; photosensitive Hautreakt.; Hauterkrank.; Hautläsion; Hautgeschwülste;
abnormes Haarwachstum; lichenoide Keratose; Hautverfärb.; Hyperpigment. d. Haut; Erythema nodosum; Pigmentstör.; Hautgeschwüre. Myositis (einschl. Myopathie u. Rhabdomyolyse); Steifheit d. Gelenke; Schwell. d. Gelenke;
Polymyalgia rheumatica; Polyarthritis; Schm. im Kiefer; Knochenschm.; Flankenschm.; Synovitis; Nackenschm.; Muskelzuck. Nephritis (einschl. Autoimmunnephritis u. tubulointerstit. Nephritis); akute Niereninsuff.; Niereninsuff.; chron.
Niereninsuff.; Pollakisurie; Dysurie. Unterleibsschm.; erektile Dysfunktion; Menorrhagie. General. Ödeme; Schm.;
Schm. im Brustkorb; Entzünd.; Gangstör.; Beschw. im Brustkorb; Wärmeunverträglichk.; Unwohlsein; Ödeme; Gesichtsödem; Xerose; Hitzegefühl; Durst. Erhöh. Werte von: Kreatinphosphokinase im Blut; GGT; Amylase; Blutglukose;
Kreatinin im Blut; Bilirubin im Blut; TSH im Blut; Trijodthyronin; Triglyzeriden im Blut; Cholesterin im Blut; freiem
Thyroxin; Transaminasen; Kalzium im Blut; erniedr. Werte von: TSH im Blut; Thyroxin. Gewichtszunahme. Selten:
Akrochordon; Neoplasmaschwell. Immunthrombozytopen. Purpura; hämolyt. Anämie; Panzytopenie. Autoimmunerkrank. Affekt. Stör.; Agitiertheit; Halluzinat.; Trance. Hirnödem; Enzephalopathie; Epilepsie; nichtinfekt.
Meningitis; Myasthenie-Syndrom; Krämpfe; Dysarthrie; fokale Krampfanfälle; Synkope. Doppeltsehen; Erkrank. d.
Auges; Erkrank. d. Augenlids; Makula-Degeneration; periorbit. Ödem; Photopsie. Lagerungsschwindel. Vorhofflimmern. Hypertonie; Lymphödem; Vaskulitis. Pleuraerguss; Kongestion d. Atemwege. Dünndarmperforation; Blutungen
im oberen GIT; Oberbauchbeschw.; Glossitis; Zahndemineral. Akne; Kontaktdermatitis. Plant. Fasziitis; Arthropathie;
Sehnenschm.; Sehnenentzünd.; Sehnenscheidenentzünd. Harninkont. Dysmenorrhö; Hämatospermie; genitaler Juckreiz; skrotales Erythem. Entzünd.-schm.; lokale Schwell.; lokal begrenztes Ödem; Reakt. an d. Infus.-stelle; Schwell.
Autoantikörper-positiv; QT-Verlängerung im EKG; verläng. aktiv. part. Thromboplastinzeit; erniedr. Testosteronwerte
im Blut; erhöh. Harnsäurewerte im Blut; erhöh. Werte von CRP; erhöh. Anzahl an Eosinophilen. Zusätzl.: diabet. Ketoazidose. Opt. Neuritis. Ther.-bedingte Antikörper. Warnhinw.: Zuverlässige Verhütungsmethode b. Frauen im gebährf. Alter bis 4 Mon. nach Behandl.-ende. Verschreibungspflichtig.
Stand: 07/2015
Bitte lesen Sie vor Verordnung von KEYTRUDA® die Fachinformation!
Pharmazeutischer Unternehmer: Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU
Vereinigtes Königreich
Lokaler Ansprechpartner: MSD SHARP & DOHME GMBH, Lindenplatz 1, 85540 Haar
Reference: 1. Robert C, Schachter J, Long GV, et al, for the KEYNOTE-006 investigators.
Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–2532.
16
Copyright © 2016 MSD SHARP & DOHME GMBH, Lindenplatz 1, 85540 Haar. www.msd.de.
Alle Rechte vorbehalten. ONCO-1172474-0000 01/16
GENERAL INFORMATION
Congress Venue
Leonardo Royal Hotel Munich, Moosacher Straße 90, 80809 Munich
Phone: +49 (0)89 2885380, E-Mail: [email protected]
www.leonardo-hotels.com/Leonardo_Royal_Hotel_Munich
Congress Date
June 30th–July 1st, 2016
Registration and Information Desk
The registration desk is situated at the ground floor of the Leonardo Royal Hotel to the left of the reception.
Registration Desk Opening Hours
Wednesday, June 29th, 2016 17:00–19:00 (early check-in)
Thursday, June 30th, 2016 08:00–20:00
Friday, July 1st, 2016
07:00–20:00
Accomodation
Individual hotel reservation: Please contact the congress hotel or one of the hotels nearby directly for your
individual room bookings. MedConcept has reserved a limited number of rooms under the reference “European
Post-Chicago Meeting 2016” in the following hotels:
Leonardo Royal Hotel Munich****
Moosacher Str. 90, 80809 Munich
Phone: +49 (0)89 62039779, Fax: +49 (0)89 62039717, E-Mail: [email protected]
Rate per standard room and night: 159 Euro single and 180 Euro double, breakfast included
Booking deadline: May 24th, 2016
Four Points By Sheraton München Olympiapark****
Helene-Meyer-Ring 12, 80809 Munich
Phone: +49 (0)89 35751750, Fax: +49 (0)89 35751755, E-Mail: [email protected]
Rate per standard room and night: 139 Euro single and 159 Euro double, breakfast included
Booking deadline: May 29th, 2016
Distance to Leonardo Royal Hotel: 1 km
All booking of rooms only according to availability! All rates include 19 % VAT!
Call for Abstracts
All those interested in presenting abstracts at the 6th European Post-Chicago Melanoma Meeting are invited to
submit their work to the Program Committee for review. Selected abstracts will be chosen for an oral presentation during the Free Communications Sessions. The best poster on display will be awarded during the congress
on July 1st at 10:25 with a poster award of 1.000 Euro. The acceptance of an abstract does not include the
congress registration. Abstracts can be submitted online at www.melanomaglobal2016.org.
Deadline Abstract Submission: May 1st, 2016
17
CME Credits
An application for CME accreditation will be made.
Cancellation Policy
Cancellations must be received in writing by May 1st, 2016. No refunds will be granted after that date. To cancel
a registration, please send an email to [email protected] and include “European Post-Chicago Melanoma
Meeting 2016 Cancellation” in the subject line. A processing fee of 30 Euro will be deducted from each cancelled
registration.
Substitutions (new ticket holder must come from the same institution) are possible and must be received in writing
by June 19th, 2016. To substitute a registration please send an email including the name of the original registrant
and the name of the person substituting to [email protected] and include “European Post-Chicago Melanoma Meeting 2016 Substitution” in the subject line.
The participant acknowledges that he/she has no right to lodge damage claims against the organizers should
the holding of the meeting be hindered or prevented by unexpected, political or economic events or generally by
force, or should the non-appearance of speakers or other reasons need program changes. With registration, the
participant accepts this proviso.
Exhibition
A commercial exhibition will be held at the congress venue, close to the main rooms.
Exhibition Opening Hours
Thursday, June 30th, 2016 09:00–18:30
Friday, July 1st, 2016
07:30–18:30
Language and Translation
The official language of the meeting will be English. Simultaneous translation will not be provided.
Insurance
The Organizer does not accept liability for individual medical, travel or personal insurance and participants are
strongly advised to make their own arrangements in respect to health and travel insurance.
Passport and Visa
For most nationalities visas are not required for entering Germany. For further information about visa and
passport please contact the German embassy in your country. If an invitation letter for visa purposes is required
please contact MedConcept.
Registration
Please visit the congress website www.melanomaglobal2016.org for online registration or fill out the registration
form on the last page of the program.
Registration Fees
Early registration
till April 5th
From April 6th
till June 19th
On site
Full Delegates
300 Euro
400 Euro
500 Euro
Doctors in training* and Eastern European Countries
200 Euro
250 Euro
300 Euro
Day Ticket 150 Euro
200 Euro
250 Euro
*Please forward appropriate documentary evidence via mail, email or fax to the congress office: MedConcept GmbH, Friedenstraße 58,
15366 Neuenhagen bei Berlin, Germany, [email protected], Fax: +49 (0)3342 42689-30
After June 19th all registrations have to be on-site at the meeting venue.
18
Important Dates
Early Registration Fee: till April 5th, 2016
Deadline Abstract Submission: May 1st, 2016
Notification of Acceptance of Abstracts: May 16th, 2016
Closing of Pre-Registration: June 19th, 2016
Congress Organization
Gesellschaft für medizinische Projekte mbH
Friedenstraße 58 · 15366 Neuenhagen bei Berlin, Germany
[email protected] · www.medconcept.org
Phone +49 (0)3342 42689-30 · Fax +49 (0)3342 42689-40
On-site cellphone numbers:
Mirja Christ: +49 (0)176 62890497
Alexandra Hansen: +49 (0)151 17161221
Christopher Huhn: +49 (0)151 17161223
www.melanomaglobal2016.org
19
SPONSORS
PLATINUM
120,000 Euro Platinum Sponsorship
120,750 Euro Platinum Sponsorship
incl. Meeting Room
120,000 Euro Platinum Sponsorship
BRONZE
FURTHER SPONSORS
Delcath Systems Limited
medac GmbH
Philogen S.p.A.
20
120,000 Euro Platinum Sponsorship
REGISTRATION FORM
June 30th–July 1st, 2016 · 6 th European Post-Chicago Melanoma /
Skin Cancer Meeting 2016 Results and Interpretations of ASCO Presentations 2016:
Interdisciplinary Global Conference on News in Melanoma/Skin Cancer
First Name: Last Name: Professional Title: Gender: Male Degree: MD PhD RN PA-C Other Female Speciality: Institution: Address: City: State: Zip Code: Daytime Telephone: Fax: Country: E-Mail: Fees (VAT included)
Early registration
till April 5th
From April 6th
till June 19th
On site
Full Delegates
300 Euro
400 Euro
500 Euro
Doctors in training* and Eastern European Countries
200 Euro
250 Euro
300 Euro
Day Ticket 150 Euro
200 Euro
250 Euro
June 30th July 1st
*Please forward appropriate documentary evidence via mail, email or fax to the congress office: MedConcept GmbH, Friedenstraße 58,
15366 Neuenhagen bei Berlin, Germany, [email protected], Fax: +49 (0)3342 42689-40
Total Amount: Euro
Payment Method
Cash (Euro): Credit Card: MasterCard Visa American Express
Credit Card Number: Expiration Date: Security Code CCV: (MC/Visa – 3 digits on back, AMEX – 4 digits on front)
Cardholder Name:
Signature: Congress Organization
Gesellschaft für medizinische Projekte mbH
Friedenstraße 58 · 15366 Neuenhagen bei Berlin
[email protected] · www.medconcept.org
Phone +49 (0)3342 42689-30 · Fax +49 (0)3342 42689-40
21
22
NOTES
23
NOTES
STRONGER
NEU: ®
LIC
COTEL
ion
inat io
in Komb af®
or
mi t Zelb
TOGETHER
Bei BRAF-mutiertem fortgeschrittenem Melanom:
Überzeugende
Langzeitwirkung1,2
1. McArthur GA et al. Eur J Cancer 2015; 51: S720–S723.
2. Atkinson V et al. SMR 2015.
 Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung. Dies ermöglicht eine schnelle Identifizierung neuer Erkenntnisse über die Sicherheit.
Sie können dabei helfen, indem Sie jede auftretende Nebenwirkung melden.
Cotellic® 20 mg Filmtabletten. Wirkstoff: Cobimetinib. Zusammensetzung: Jede Filmtablette enthält Cobimetinibhemifumarat, entsprechend 20 mg Cobimetinib.
Sonstige Bestandteile: Tablettenkern: Lactose-Monohydrat , Mikrokristalline Cellulose, Croscarmellose-Natrium, Magnesiumstearat; Tablettenüberzug: Poly(vinylalkohol), Titandioxid, Macrogol und Talkum. Anwendungsgebiet: Cotellic wird in Kombination mit Vemurafenib angewendet zur Behandlung bei erwachsenen Patienten mit nicht resezierbarem oder metastasiertem Melanom mit einer BRAF-V600-Mutation. Gegenanzeigen: Überempfindlichkeit gegen den Wirkstoff oder sonstige
Bestandteile. Nebenwirkungen: Sehr häufig: Blutarmut, seröse Retinopathie, Bluthochdruck, Blutungen, Übelkeit, Erbrechen, Lichtempfindlichkeit, makulopapulöser
Ausschlag, Akne-ähnlicher Ausschlag, Hyperkeratose, Fieber, erhöhte Leberenzymwerte, Anstieg der CPK. Häufig: kutanes Basalzellkarzinom, Plattenepithelkarzinom, Keratoakanthom, Dehydration, Hypophosphatämie, Hyponatriämie, Hyperglykämie, Pneumonitis, Schüttelfrost, verminderte Auswurffraktion, erhöhter Bilirubinwert im Blut. Warnhinweise: Bevor mit der Anwendung von Cotellic in Kombination mit Vemurafenib begonnen wird, muss ein durch einen validierten Test bestätigter BRAF-V600-Mutation-pos. Tumorstatus vorliegen. Bei Problemen mit den Augen, dem Herz oder der Leber vor der Einnahme den behandelnden Arzt konsultieren.
Bei Durchfall umgehend den behandelnden Arzt konsultieren. Arzneimittel für Kinder unzugänglich aufbewahren. Enthält Lactose. Dosierung: Die empfohlene Dosis
von Cotellic beträgt einmal täglich 3 Tabletten (insgesamt 60 mg). 21-tägiger Behandlungszyklus gefolgt von 7-tägiger Behandlungspause. Verschreibungspflichtig.
Hinweise der Fachinformation beachten. Pharmazeutischer Unternehmer: Roche Registration Limited, Welwyn Garden City, Vereinigtes Königreich. Weitere Informationen auf Anfrage erhältlich. Vertreter in Deutschland: Roche Pharma AG, 79630 Grenzach-Wyhlen. Stand der Information: Dezember 2015
24
Erfahren Sie
mehr unter
www.cotellic.de
LAYOUT UND DRUCK: MEDIASERVICE GMBH DRUCK UND KOMMUNIKATION
FOTOS: TITELBILD: VISUALSUNLIMITED/DOC-STOCK · S4/5 ISTOCKPHOTO/SBORISOV, MANFREDXY, XYNO MÜNCHEN (2) · S6/7 PIXELIO.DE/ PETRA DIRSCHERL, GERHARD PRANTL, FLICKR ST. DAMENKAPELLE
S8/9 ISTOCKPHOTO/SEEWHATMITCHSEE, ALEXM156, PIXELIO.DE/ALEXANDER HAUK – BAYERN.NACHRICHTEN.DE · S10 ISTOCKPHOTO/SVEN PETER, PIXELIO.DE/HARTMUT910

Similar documents